Johnson & Johnson has announced that its drug nipocalimab demonstrated statistically significant and clinically meaningful improvements in a Phase II study for 18 June 2024
Belgium’s UCB is sharing results from three studies supporting the value of Cimzia (certolizumab pegol) for women of childbearing age living with chronic immune 13 June 2024
One of the most important medical meetings in rheumatology is underway in Vienna, Austria, and leading drugmakers in the field have lifted the lid on data they 12 June 2024
Belgian biotech UCB has presented promising two-year data from Phase III studies on Bimzelx (bimekizumab) at the European Congress of Rheumatology, EULAR 2024. 12 June 2024
Korean biosimilar company Samsung Bioepis is presenting new data on its copy of Humira (adalimumab), which is branded as Imraldi and Hadlima and also referred t 1 June 2022
At the annual European Congress of Rheumatology (EULAR 2022), presentations will include new data from two Phase III studies of bimekizumab, BE MOBILE 1 and BE 23 May 2022
Russian pharma company R-Pharm has highlighted the views of four leading rheumatologists on its rheumatoid arthritis (RA) drug candidate olokizumab, which succe 7 June 2021
Pharma giant Novartis has announced full positive results from the Phase III PREVENT trial of Cosentyx (secukinumab) in axial spondyloarthritis. 4 June 2020
For Belgium-based drugmaker UCB (Euronext: UCB), EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing a 21 June 2019
Now that the warming Spanish sun has gone down on EULAR 2019, it’s worth considering what emerged of note from some of rheumatology’s leading players at the eve 20 June 2019
An oral presentation at the annual meeting of the European Congress of Rheumatology (EULAR) has detailed positive results from a Phase III study of brodalumab ( 17 June 2019
Indian drugmaker Sun Pharmaceutical Industries’ Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR 14 June 2019
Bimekizumab is a crucial pipeline drug for UCB – allowing the company’s to look beyond Cimzia (certolizumab pegol) in immunology – so each successful data read- 14 June 2019
US pharma major Eli Lilly presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s Humira (a 13 June 2019
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.